The purpose of the study is to find out whether PIPE-791 can preserve breathing ability better than the placebo. Participants will take the study medication or placebo every day for about six months, with regular visits to check health, report any side effects, and undergo simple breathing tests. One of the key breathing tests measures forced vital capacity (FVC), which is the amount of air a person can push out of the lungs after taking a deep breath; this helps doctors see how the lungs are working. At selected visits, a special detailed X‑ray scan called HRCT will be used to look at the amount of scarring in the lungs. The study follows participants for the full treatment period to monitor safety and how well the drug works.

The purpose of the study is to assess the antitumor activity and safety of Rinatabart Sesutecan in participants with these advanced cancers. Participants will receive the study drug at regular intervals while being monitored through clinic visits, blood tests, and imaging scans to check for changes in tumor size and to record any side effects, known as adverse events. The study follows a schedule that spans several months, allowing researchers to observe how the cancer responds over time and to gather information on the medication’s tolerability.

The purpose of the study is to evaluate whether the medication can reduce excessive daytime sleepiness in people with the condition. Participants are randomly assigned to receive either the active drug or the placebo during a double‑blind phase, meaning neither the participants nor the study staff know which treatment is being taken. After this period, all participants may enter an open‑label extension where everyone receives the active medication, with regular visits to monitor safety and symptom changes over several months.

The purpose is to compare how well the cancer is controlled when the experimental drug is added to chemotherapy versus chemotherapy alone. After enrollment, participants are randomly assigned to one of the two groups, take the study medication daily in tablet form, and undergo regular clinic visits for treatment cycles and safety checks. The study continues until the disease progresses, the participant stops treatment, or the study ends, with follow‑up visits to monitor overall health and any side effects.

The purpose of the study is to determine whether the investigational drug improves symptoms compared with the control. Participants are randomly assigned to receive either the medication or the placebo, and neither the participants nor the study staff know which is given (double‑blind). The drug is administered by a small injection under the skin (subcutaneous) on a regular schedule over several weeks, with follow‑up visits to check health and record daily bowel habits.

During the study, participants keep a simple diary of stool frequency, consistency, and pain, and they attend periodic clinic visits for safety checks, such as brief physical examinations and basic laboratory tests. The overall study period lasts about four months, after which the collected information is used to assess the medication’s effect on the condition.

The main goal of the trial is to find out whether the medication can slow the increase in the size of the damaged areas of the retina. The study is designed so that participants are randomly assigned to receive either the active drug or the placebo, and neither the participants nor the study staff will know which treatment is given. The trial will last about two years, with regular clinic visits for assessments.

During the study, participants will take one capsule each day and attend scheduled visits where several eye tests are performed. A special camera called FAF will take pictures that highlight unhealthy retinal tissue, while an imaging technique known as OCT will create cross‑sectional views of the eye’s layers. Vision will be measured using a standard eye chart (ETDRS) to determine BCVA, and low‑light reading ability will also be checked. Reading speed will be evaluated with two tests, IReST and MNRead. Sensitivity of the retina will be mapped with microperimetry, and participants will complete questionnaires such as the NEI-VFQ-25 to report how the condition affects daily activities.

The purpose of the study is to assess how safe the medicine is and whether it shows early signs that it can shrink tumors when used alone or with the hormone blocker. Participants start with low doses that are gradually increased while doctors watch for side effects, known as dose‑limiting toxicities, and determine the highest dose that can be given safely, called the maximum tolerated dose. After the safe dose is found, more patients receive that dose for several treatment cycles, with regular clinic visits, blood tests, and imaging scans to see if the tumors are responding. The study follows a phase 1/2 trial design, beginning with a safety‑focused part and then moving to a larger group to look at tumor response and how long the benefit lasts.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

The purpose of the study is to determine whether adding the drug to the usual treatment, called standard of care, lowers the risk of returning to the hospital, visiting the ED, or dying after the flare‑up. After discharge, participants are randomly assigned to one of the two groups and receive injections at regular intervals while researchers check in with them through clinic visits and phone calls over several months.

Researchers will track how often participants experience another worsening of symptoms, known as an exacerbation, and will record any unplanned hospital readmissions, urgent care visits, or deaths. They will also ask participants to complete simple questionnaires that measure how the lung disease affects daily life and symptom severity. Any side effects or health problems that appear during the study will be recorded and evaluated.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

The main aim is to determine whether Brenipatide improves symptoms compared with placebo. Participants are assigned by chance to receive either the study drug or the placebo, and the trial is conducted in a double‑blind manner so that neither the participants nor the study staff know which treatment is administered. After a short screening period, injections are given regularly for several weeks, and participants attend clinic visits to report how they feel and to have safety checks.

Throughout the 16‑week period, the study records how many weeks each participant experiences a meaningful reduction in pain and stool difficulty, and it monitors any side effects. The collected information will help decide if the medicine is both effective and safe for people with this type of irritable bowel syndrome.

The purpose of the study is to determine whether the experimental drug can restore a normal heart rhythm, known as sinus rhythm. In the trial, adult participants are randomly assigned to receive either the study drug or the placebo. The assigned treatment is delivered by a short intravenous infusion, and participants are observed for at least three hours to see if their heart rhythm changes from the irregular pattern to a steady one without needing additional procedures. Safety checks are performed throughout the visit, and a blood sample is taken at the end of the infusion to measure how much of the medicine is present in the body.

The purpose of the study is to determine if the drug combination improves the way blood moves through the body in people with a Fontan circulation. Participants will receive either the active medicines or the placebo for a defined period and will attend regular clinic visits where simple tests are performed, including measurements of peripheral venous pressure (the pressure in the veins that indicates how much fluid is backing up) and pulmonary capillary wedge pressure (a reading that reflects the pressure inside the left side of the heart). Blood samples, basic exercise assessments, and safety checks such as blood chemistry will also be done to monitor how the body responds and to watch for any side effects.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to determine whether adding intra‑operative metamizole reduces the amount of opioid (a strong pain‑relieving drug often used after surgery) needed in the first few hours after surgery. Participants are randomly assigned to receive either the study drug or placebo, remain unaware of which they received, and have their pain levels recorded regularly. The primary measure is the total morphine (measured as milligram equivalents, a standard way to compare the strength of different opioid doses) consumed during and for three hours after the operation, with additional observations of rescue pain medication use, time to discharge, and overall pain scores up to 48 hours.

The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

Participants in the study will receive BI 3032950 initially through an intravenous (IV) method, which means the medication is delivered directly into a vein. After this induction phase, the treatment will continue with subcutaneous (SC) injections, where the medication is injected under the skin. The study will monitor patients over a period of time to see if they achieve clinical remission, which means a significant reduction or disappearance of symptoms, by Week 12. The study will also look at other outcomes, such as improvements seen during an endoscopy, a procedure that uses a camera to view the inside of the colon.

Throughout the study, researchers will keep track of any side effects or adverse events that may occur. The trial is designed to last up to 104 weeks, allowing for a comprehensive assessment of the treatment’s long-term effects. This study aims to provide valuable insights into whether BI 3032950 can be a beneficial treatment option for those suffering from ulcerative colitis.

After enrollment, participants will start the assigned medication within three days of the brain bleed and will continue taking it for several months. Throughout the study, they will have regular check‑ins to monitor health, including assessments of disability using the modified Rankin Scale, cognitive function with the Montreal Cognitive Assessment, and overall quality of life via the EQ-5D-5L questionnaire. The study will track any new strokes, heart attacks, or procedures to restore blood flow, as well as survival and the level of dependence on others at six months.

Participants receive the assigned medication for several months and attend regular clinic visits where blood samples and imaging are performed to monitor the cancer and any side effects. A laboratory test called Ki-67 is used to measure how quickly cancer cells are dividing; a higher level means faster growth. The term ovarian cysts refers to fluid‑filled sacs that can develop on the ovaries and sometimes cause pain or other symptoms. Throughout the study, safety checks and symptom assessments are conducted to ensure participant well‑being.

The purpose of the study is to determine which of the two therapies works better at controlling the disease. Participants will be randomly assigned to receive one of the two treatments, followed by regular check‑ups that may include scans such as positron emission tomography-computed tomography to look for any remaining cancer and assessments of overall health and quality of life. The study continues for several months after treatment to monitor how well the disease is controlled and to record any side effects.

The purpose is to find out how safe the medicines are and whether they can lower the activity of the cancer. Adults whose disease has returned after earlier therapy (relapsed) or does not respond to usual medicines (refractory) will receive the study drugs for several treatment cycles. Participants will have regular doctor visits, blood tests, and scans to watch for side effects and to see if the cancer shrinks. Terms like “biomarker‑selected” mean that a laboratory test is used to choose patients whose cancer has a specific characteristic; “dose limiting toxicity” describes side effects that stop the dose from being increased; and “overall response rate” is the percentage of patients whose cancer gets smaller or disappears.

The purpose of the study is to find out whether this new scan can accurately identify deep or superficial endometriosis compared with the current standard method, which is a small‑incision surgical examination known as laparoscopy. Participants will have the injection and scan, and later will undergo the routine surgical procedure so the two sets of findings can be compared. Additional routine imaging tests such as MRI or ultrasound may also be done if they are already part of the patient’s care.

After the initial scan, participants may have a second scan if they start hormone‑blocking medication (often called a GnRH‑agonist or GnRH‑antagonist) to see how the disease changes. Throughout the study, safety is monitored and any side effects are recorded. The overall aim is to determine if this non‑invasive imaging approach can help doctors diagnose and manage endometriosis more effectively.

The purpose of the study is to determine the safety and tolerability of these regimens in people with this condition. Participants are randomly assigned to receive either the active medication or the placebo, and neither the participants nor the study staff know which treatment is given. Over a period of several weeks, participants attend regular visits where vital signs, laboratory tests, and symptom questionnaires such as the MG-ADL (a simple survey that asks about daily activities affected by muscle weakness) are collected to monitor any side effects and changes in disease symptoms.

The purpose of the study is to see whether lunsekimig can reduce the number of moderate to severe flare‑ups of the lung disease over a year. After enrollment, participants will be randomly assigned to one of the two groups and will attend regular clinic visits for injections, safety checks, and simple breathing tests over several months.

A flare‑up, or exacerbation, means a sudden worsening of breathing problems that often requires extra medication or a hospital visit. The term Forced Expiratory Volume in 1 second refers to a common breathing test that measures how much air a person can force out of their lungs in one second; it helps doctors track lung function. The eosinophilic pattern is identified by a blood test that shows higher eosinophil counts, which can influence how the disease behaves and responds to treatment.

Participants will first receive a single low dose of the medication, followed by a period of observation. After this initial phase, they may receive multiple increasing doses over several weeks, with regular clinic visits to check how the drug is processed in the body and to record any changes in seizure frequency. Samples of the fluid around the brain and spinal cord (CSF) and blood are taken to understand how the drug moves through the body, and seizure counts are recorded to see if there is any improvement. Throughout the study, doctors closely watch for any adverse events and adjust the plan as needed.

The aim of the study is to evaluate the safety and tolerability of long‑term use of this medication. Participants who have previously taken part in an earlier trial will continue to receive the inhaled powder and will be followed for up to two years. During this time they will attend regular clinic visits where simple checks such as blood tests, heart rhythm monitoring (ECG), measurement of oxygen use, and basic physical examinations are performed. The study also includes a group receiving placebo for comparison.

Throughout the study, participants will undergo a short walking test (6MWD) to see how far they can walk in six minutes, and lung function tests that measure the amount of air they can force out (FVC) and the speed of airflow (FEV1). Blood samples will be taken to check levels of a heart‑stress marker (NT-proBNP). These assessments help researchers understand how the medication affects breathing ability, heart strain, and overall health over the long term.

The main aim is to see whether the medicine can keep the cancer from coming back compared with the placebo, measured by the length of time patients stay free of disease, known as DFS. Participants will take the study medication for a set period, return for regular check‑ups, and have routine tests such as scans and lab work to monitor their health.

In addition to tracking if the cancer returns, the study will also look at overall survival, which is how long participants live after treatment, referred to as OS, and whether the disease spreads to the CNS. Safety will be watched by recording any side effects using a standard grading system (CTCAE) and by performing simple heart rhythm checks (ECG). The study follows participants for several years to gather this information.

The purpose of the study is to evaluate safety and find the best dose of the new medicines when used alone or in combination. Participants receive an IV infusion, which means the medicine is delivered directly into a vein, and they swallow tablets on a regular schedule. Treatment cycles are repeated every few weeks, and patients return to the clinic for regular check‑ups, blood tests, and simple examinations to watch for any side effects.

Participants are randomly assigned to receive either Enpatoran or placebo for a period of 24 weeks while continuing any usual care. The skin severity is measured using the CLASI score, which rates the extent and intensity of rash, and overall lupus activity is also evaluated with the BICLA assessment. Throughout the study, safety is monitored by recording any adverse events and laboratory changes. Visits occur at regular intervals to collect the necessary information and to ensure participant well‑being.

The purpose of the study is to compare the safety of flecainide with that of the standard anti‑arrhythmic drugs in this patient group. After a short screening period, participants will start taking the assigned medication and will have regular clinic visits for check‑ups over a minimum of one year. During the study, doctors will record any serious problems such as death, need to stop the medication because of side effects, or unexpected hospital stays for heart failure or heart attacks.

Safety will be evaluated using several heart‑related measurements. The study will look at the QTc interval, a number on an electrocardiogram (ECG) that shows how long the heart’s electrical system takes to recharge, and the QRS duration, which reflects how quickly the heart’s electrical signal spreads. Heart‑pumping ability will be checked with the left ventricular ejection fraction, and a blood test called NT-proBNP will be used to see if the heart is under stress. Major adverse cardiovascular events, often abbreviated as MACE, such as heart‑related death, non‑fatal heart attacks, or strokes, will also be tracked.

Participants will receive their assigned medicines on a regular schedule, with IV infusions given at the clinic and oral tablets taken at home. Throughout the study, doctors will perform routine checks, imaging scans, and questionnaires to monitor tumor size, side effects, and overall health. The trial continues until a predefined number of assessments are completed or until a participant stops treatment, after which follow‑up visits assess long‑term outcomes.

The purpose of the study is to compare how well the new cell‑based therapy works against these standard medicines in improving lung function. Participants are randomly assigned to receive either the experimental treatment or the usual care, and both groups are observed over several months to see changes in breathing ability and skin condition.

During the study, lung capacity is measured using Forced Vital Capacity, which records the amount of air a person can blow out after a deep breath. Participants visit the clinic at regular intervals for safety checks, blood tests, and simple examinations of skin thickness. The overall follow‑up period lasts about a year, allowing researchers to track how the disease progresses or improves.

The main goal of the trial is to evaluate the long‑term safety and tolerability of the study drug in people with the condition. After an initial screening, participants receive the medication at regular intervals for an extended period, during which doctors monitor vital signs, blood tests, heart recordings, and physical examinations. Simple walking and climbing tests are performed at the start and at later visits to see how the treatment may affect mobility.

Throughout the study, blood samples are taken to measure how much of the medicine remains in the body and to check for any immune response. All observations are recorded to help determine whether the therapy is safe for continued use over time.

The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

The purpose of the study is to assess the safety and tolerability of these treatment regimens. Participants will receive a single injection at the start and then continue receiving additional injections according to a fixed schedule over many months. Regular visits will be scheduled to check health status, and an examination of the intestine using a camera (often called an endoscopy) will be performed around week 48 to see how the lining has responded.

Throughout the trial, researchers will closely watch for any side effects that arise after treatment and will record any new health problems. The endoscopic examination will help determine whether the inner surface of the colon shows signs of healing, providing an indication of how well the medication may be working while ensuring participants remain safe.

Participants are randomly assigned to receive either the combination therapy or a single oral drug, and treatment continues until disease progression or unacceptable side effects occur. Visits include regular health checks, blood tests, and imaging scans to monitor the tumor and overall health. The study follows patients for several months to record how long they live, how long the disease stays stable, and any side effects that arise.